Ultragenyx reports preliminary 2022 revenue $352-$356M; guides 2023 revenue $425-$450M

Ultragenyx Pharmaceutical Inc.

2022-FY EPS reported -$10.12 revenue$363,329,000

Preliminary 2022 total product revenue $352M-$356M; Crysvita territories $257M-$258M; Dojolvi $55M-$56M.
2023 revenue guidance $425M-$450M; Crysvita $325M-$340M; Dojolvi $65M-$75M; net cash used ops <$400M.
Year-end 2022 cash ~$900M; non-recurring items included $90M capex, $75M GeneTx acquisition, $30M Evkeeza license.
Pipeline: UX143 Phase 2 data mid-2023; DTX301 Phase 3 start Q1 2023; UX701 Stage 1 enrollment mid-2023; DTX401 Phase 3 data H1 2024.
Crysvita guidance reflects 20% YoY growth; royalties from Europe and North America (starting April 2023) included.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ultragenyx Pharmaceutical Inc. reported 2023 results: revenue $425 million to $450 million. Guidance initiated.

Period: 2023
Revenue: $425 million to $450 million
Guidance: initiated
Result: guidance update

Exact text from the filing

2023 expected Total Product Revenue guidance between $425 million to $450 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ultragenyx Pharmaceutical Inc. reported fiscal year 2022 results: revenue $352 million to $356 million.

Period: fiscal year 2022
Revenue: $352 million to $356 million
Result: preliminary results

Exact text from the filing

Preliminary 2022 Total Product Revenue of $352 million to $356 million

View on SEC.gov

Browse all earnings releases →

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.